There is wide variation in published guidelines for posttreatment surveillance of colorectal cancer (CRC) to detect recurrence. Variation also exists for recurrence risk (<10% to >50%), life expectancy, eligibility/willingness for salvage therapy, and preferences regarding surveillance. There is a need for improved evidence regarding the effectiveness of surveillance and a need to develop a patient-centered individualized approach.
